EJSO educational special issue from the TARPSWG: standard medical treatment and new options in retroperitoneal sarcoma

Retroperitoneal soft tissue sarcomas mainly consist histologically of liposarcomas and leiomyosarcomas. For the liposarcoma subgroup, the local relapse rate seems to determine patients' overall prognosis. In contrast, leiomyosarcoma patients are challenged by the development of metastatic disea...

Full description

Saved in:
Bibliographic Details
Main Authors: Kasper, Bernd (Author) , Baldi, Giacomo Giulio (Author) , Loong, Herbert Ho-Fung (Author) , Trent, Jonathan (Author)
Format: Article (Journal)
Language:English
Published: June 2023
In: European journal of surgical oncology
Year: 2023, Volume: 49, Issue: 6, Pages: 1133-1139
ISSN:1532-2157
DOI:10.1016/j.ejso.2021.12.465
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejso.2021.12.465
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0748798321014372
Get full text
Author Notes:Bernd Kasper, Giacomo Giulio Baldi, Herbert Ho-Fung Loong, Jonathan Trent
Description
Summary:Retroperitoneal soft tissue sarcomas mainly consist histologically of liposarcomas and leiomyosarcomas. For the liposarcoma subgroup, the local relapse rate seems to determine patients' overall prognosis. In contrast, leiomyosarcoma patients are challenged by the development of metastatic disease; therefore, effective systemic therapies are the cornerstone to improve patients’ outcome. No doubt, the limited number of active regimens currently available makes the treatment of patients with locally advanced and/or metastatic disease challenging and results in the overall poor prognosis of this population. In this European Journal of Surgical Oncology Educational Special Issue from the Transatlantic Australasian RetroPeritoneal Sarcoma Working Group (TARPSWG), we aim to summarize state-of-the-art systemic treatments for patients with retroperitoneal sarcomas with a focus on the locally advanced and metastatic disease setting including conventional standard chemotherapies as well as new innovative treatment approaches in order to identify current unmet medical needs guiding the sarcoma community to initiate appropriate translational research projects and design innovative clinical trials.
Item Description:Online verfügbar: 31. Dezember 2021, Artikelversion: 24. Mai 2023
Gesehen am 11.09.2024
Physical Description:Online Resource
ISSN:1532-2157
DOI:10.1016/j.ejso.2021.12.465